Integrating Multi-Cancer Early Detection Tests Into Clinical Practice: The Health Economics Perspective for Managed Care Professionals
Episode 3, Jul 22, 01:41 PM
To view the article and claim CE credit for this activity, click here.
In the United States, almost half of cancers are preventable, and early detection would allow for cancer treatment to be more effective both in cost and patient outcomes; however, established cancer screening tools are underutilized. Blood-based technologies, known as multi-cancer early detection (MCED) tests, can identify multiple cancers early and simultaneously. As more is revealed about the significance of early cancer detection, it becomes evident that MCED tests not only promise to enhance patient outcomes, but can also optimize health care resource allocation and reduce the socioeconomic burden of cancer. When utilized appropriately, these MCED technologies have the potential to detect a higher proportion of early-stage treatment-amenable cancers. It is imperative that managed care professionals are educated about the recent and ongoing advancements in the field of oncology to spearhead the integration of MCED technologies into care of cancers that do not have a screening method and are often diagnosed in advanced stages. This activity will provide managed care professionals with the tools and resources needed to identify and address the various barriers and health disparities that contribute to low rates of cancer screenings, offer a deeper insight into the cost-effectiveness of novel MCED tests, and equip them with knowledge of the clinical and economic benefits associated with early cancer detection and treatment.
In the United States, almost half of cancers are preventable, and early detection would allow for cancer treatment to be more effective both in cost and patient outcomes; however, established cancer screening tools are underutilized. Blood-based technologies, known as multi-cancer early detection (MCED) tests, can identify multiple cancers early and simultaneously. As more is revealed about the significance of early cancer detection, it becomes evident that MCED tests not only promise to enhance patient outcomes, but can also optimize health care resource allocation and reduce the socioeconomic burden of cancer. When utilized appropriately, these MCED technologies have the potential to detect a higher proportion of early-stage treatment-amenable cancers. It is imperative that managed care professionals are educated about the recent and ongoing advancements in the field of oncology to spearhead the integration of MCED technologies into care of cancers that do not have a screening method and are often diagnosed in advanced stages. This activity will provide managed care professionals with the tools and resources needed to identify and address the various barriers and health disparities that contribute to low rates of cancer screenings, offer a deeper insight into the cost-effectiveness of novel MCED tests, and equip them with knowledge of the clinical and economic benefits associated with early cancer detection and treatment.